Srinivas R. Viswanathan, MD, PhD

Srinivas R. Viswanathan, MD, PhD

Medical Oncology

Contact Information

Office Phone Number





877-332-4294 (new)



Assistant Professor of Medicine, Harvard Medical School


Clinical Interests

Genitourinary oncology, Prostate cancer

Board Certification

  • Hematology, 2017
  • Internal Medicine, 2014
  • Medical Oncology, 2017


  • Dana-Farber/Partners CancerCare, Hematology/Oncology


  • Massachusetts General Hospital, Internal Medicine

Medical School

  • Harvard Medical School

Recent Awards

  • Jane C. Wright Endowed Young Investigator Award, American Society for Clinical Oncology
  • Physician Research Award, Prostate Cancer Research Program, Department of Defense
  • Young Investigator Award, Prostate Cancer Foundation


    • Genome-guided discovery of cancer therapeutic targets. Cell Rep. 2023 Aug 29; 42(8):112978. View in: Pubmed

    • A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma. bioRxiv. 2023 Aug 06. View in: Pubmed

    • Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematol Oncol Clin North Am. 2023 10; 37(5):1027-1040. View in: Pubmed

    • Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematol Oncol Clin North Am. 2023 10; 37(5):1015-1026. View in: Pubmed

    • Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist. 2023 05 08; 28(5):433-439. View in: Pubmed

    • Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist. 2022 12 09; 27(12):1041-1047. View in: Pubmed

    • Somatic XIST activation and features of X chromosome inactivation in male human cancers. Cell Syst. 2022 Nov 16; 13(11):932-944.e5. View in: Pubmed

    • Patterns of structural variation define prostate cancer across disease states. JCI Insight. 2022 09 08; 7(17). View in: Pubmed

    • How splicing confers treatment resistance in prostate cancer. Elife. 2022 08 23; 11. View in: Pubmed

    • A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Rep. 2022 02 22; 38(8):110417. View in: Pubmed

    • Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022 01 04; 38(1):110190. View in: Pubmed

    • TSC2 regulates lysosome biogenesis via a non-canonical RAGC and TFEB-dependent mechanism. Nat Commun. 2021 07 12; 12(1):4245. View in: Pubmed

    • Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808. View in: Pubmed

    • Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020 08; 52(8):790-799. View in: Pubmed

    • Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943. View in: Pubmed

    • Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018 07 12; 174(2):433-447.e19. View in: Pubmed

    • Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 07 27; 547(7664):453-457. View in: Pubmed

    • Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017 Apr; 4(4):e157-e164. View in: Pubmed

    • LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. Genes Dev. 2015 May 15; 29(10):1074-86. View in: Pubmed

    • Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet. 2010 Jul; 42(7):626-30. View in: Pubmed

    • Gallbladder lymphoma. Med Oncol. 2011 Sep; 28(3):810-2. View in: Pubmed

    • Lin28: A microRNA regulator with a macro role. Cell. 2010 Feb 19; 140(4):445-9. View in: Pubmed

    • Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation. J Biol Chem. 2009 Oct 23; 284(43):29269-82. View in: Pubmed

    • A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature. 2009 Aug 13; 460(7257):909-13. View in: Pubmed

    • microRNA expression during trophectoderm specification. PLoS One. 2009 Jul 03; 4(7):e6143. View in: Pubmed

    • Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8. View in: Pubmed

    • Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem. 2008 Aug 01; 283(31):21310-4. View in: Pubmed

    • Ras-MAPK signaling promotes trophectoderm formation from embryonic stem cells and mouse embryos. Nat Genet. 2008 Jul; 40(7):921-6. View in: Pubmed

    • Selective blockade of microRNA processing by Lin28. Science. 2008 Apr 04; 320(5872):97-100. View in: Pubmed

    • N-linked glycosylation is required for optimal function of Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6. J Exp Med. 2004 Feb 16; 199(4):503-14. View in: Pubmed


    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Srinivas R. Viswanathan, MD, PhD

    About Our Ratings

    Physician Star Rating Comment Block